These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25935535)

  • 1. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
    Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
    Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
    Feng X; Li H; Kornaga EN; Dean M; Lees-Miller SP; Riabowol K; Magliocco AM; Morris D; Watson PH; Enwere EK; Bebb G; Paterson A
    Oncotarget; 2016 Dec; 7(52):85798-85812. PubMed ID: 27741524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC.
    Petersen LF; Klimowicz AC; Otsuka S; Elegbede AA; Petrillo SK; Williamson T; Williamson CT; Konno M; Lees-Miller SP; Hao D; Morris D; Magliocco AM; Bebb DG
    Oncotarget; 2017 Jun; 8(24):38326-38336. PubMed ID: 28418844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
    Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
    Bueno RC; Canevari RA; Villacis RA; Domingues MA; Caldeira JR; Rocha RM; Drigo SA; Rogatto SR
    Ann Oncol; 2014 Jan; 25(1):69-75. PubMed ID: 24285016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
    Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
    Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors.
    Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S
    Int J Clin Oncol; 2019 Dec; 24(12):1526-1535. PubMed ID: 31377937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
    Rondeau S; Vacher S; De Koning L; Briaux A; Schnitzler A; Chemlali W; Callens C; Lidereau R; Bièche I
    Br J Cancer; 2015 Mar; 112(6):1059-66. PubMed ID: 25742469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
    Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
    Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.